Navigation Links
New Advances and Opportunities in Managing Pain: Translational Animal Models, New Webinar Hosted by Xtalks
Date:6/12/2013

Toronto, Canada (PRWEB) June 12, 2013

Animal models provide pivotal systems for the preclinical study of pain. Recently, there has been increased attention and discussion focused on the lack of translation of potential pain therapeutics from preclinical models to clinical settings. Measures of pain within these models have typically relied on evoked withdrawal responses to noxious stimuli (hyperalgesia) or normally non-noxious stimuli (allodynia). There have been new efforts in enhancing translation of preclinical findings to the clinical chronic pain condition. Additionally, novel measures of pain behaviors are being developed within animal pain models to better address the multidimensional aspect of pain.

This webinar reviews the challenges and current opportunities in pain research focusing on chronic pain. Chronic pain patients, especially those with neuropathic pain and cancer pain, are often not adequately treated by analgesics now on the market. Additionally, the adverse side effect profiles of the most commonly used medications, such as opiates, can further diminish quality of life in these patients. These issues emphasize the need for development of new, mechanism based therapeutics.

This event features experts with experience working with preclinical models of chronic pain including nerve injury, chemotherapy, bone cancer, and osteoarthritis. An overview of recent advances in preclinical measures of pain will be presented, including new assays of spontaneous or ongoing pain that is not evoked by stimuli applied by the experimenter.

Join us for a comprehensive presentation and interactive Q&A session!

To learn more about the event, visit: http://xtalks.com/Translational-Animal-Models-of-Pain.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/6/prweb10818147.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. EGEN, Inc. Advances a Systemically Delivered RNAi Therapeutic for the Treatment of Pulmonary Arterial Hypertension (PAH)
2. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
3. R. Graham Cooks Wins Dreyfus Prize in the Chemical Sciences; Purdue Chemist Honored for Advances in Chemical Instrumentation
4. PathoGenetix Advances Commercialization of New RESOLUTION Microbial Genotyping System for Rapid Bacterial Serotyping and Strain Typing
5. Latest Advances in Treatment for Alzheimers, Traumatic Brain Injury and Stroke to Be Presented at Symposium
6. arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders
7. Cancer Advances Announces Issuance of Three New Patents to Its Suite of Gastrin Inhibitor Products
8. SPIE Counts Advances in Sustainable Photonics on List of Solutions to Celebrate on Earth Day
9. Advances in Molecular Testing Offer New Hope for Lung Cancer Patients
10. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
11. In Focus with Martin Sheen Exploring the Advances of Molecular Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
(Date:3/22/2017)... Mass. , March 22, 2017 Good ... that it has eclipsed the 130 million covered lives ... Blue Shield of Texas . With ... the Company continues to enjoy strong payor acceptance based ... its clinical programs and genetic counseling, its industry-leading customer ...
Breaking Biology Technology:
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
Breaking Biology News(10 mins):